Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) - Vertex
Late-Diagnosed Cystic Fibrosis in an Octogenarian With an Atypical Phenotype of Pancreatic Sufficiency and Preserved Pulmonary Function. (PubMed, Cureus) - Sep 11, 2026 - "Management included airway clearance with an oscillatory positive expiratory pressure device, individualized bronchodilator therapy due to tachycardia with albuterol, surveillance respiratory cultures, nutritional and weight monitoring, otolaryngology follow-up for chronic sinusitis and nasal polyps, osteoporosis management, and treatment with vanzacaftor/tezacaftor/deutivacaftor, to which she reported symptomatic improvement. This case highlights an uncommon late-diagnosed CF phenotype in an octogenarian with pancreatic sufficiency, intermediate sweat chloride, chronic sinopulmonary disease, preserved lung function, and new isolation of Pseudomonas aeruginosa. The case emphasizes that preserved pancreatic function and advanced age do not exclude CF and that adult patients with chronic bronchiectasis, sinus disease, and atypical respiratory infections should be evaluated for CFTR dysfunction when clinically appropriate." 
Journal • Bronchiectasis • Cardiovascular • Chronic Rhinosinusitis With Nasal Polyps • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Musculoskeletal Diseases • Nasal Polyps • Orthopedics • Osteoporosis • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Rheumatology • Sinusitis • CFTR
http://www.ncbi.nlm.nih.gov/pubmed/42719490
 
Brenda Hranec; Daniel Layish; Luke Hudson
 
Sep 11, 2026
 
Prev Next